GenMark ePlex® RP2 Panel Predicted to Detect Known SARS-CoV-2 Variants Currently in Circulation Based on in silico Analysis

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) — GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently in circulation.

Click to view original post

Advertise With Us